Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH)

Medicine & Life Sciences

• Acarbose 100%
• Non-alcoholic Fatty Liver Disease 75%
• Insulin Resistance 40%
• Metabolic Syndrome 19%
• Hyperglycemia 19%
• Fatty Liver 14%
• Fatty Acids 11%
• Therapeutics 11%
• Glucosidases 10%
• Type 2 Diabetes Mellitus 10%
• Hypertension 9%
• Blood Pressure 8%
• Lipolysis 8%
• Abdominal Obesity 7%
• Insulin-Secreting Cells 7%
• Glucose Intolerance 7%
• Nonesterified Fatty Acids 7%
• Liver 7%
• Cell Wall 7%
• Waist Circumference 7%
• Insulin Secretion 6%
• Adipocytes 6%
• Lipid Peroxidation 6%
• Carbohydrates 6%
• Liver Diseases 5%
• Triglycerides 5%
• Reactive Oxygen Species 5%
• Disease Progression 5%
• Meta-Analysis 5%
• Oxidative Stress 5%
• Myocardial Infarction 5%
• Cardiovascular Diseases 5%
• Body Mass Index 5%